Press Releases

Aug 29, 2012

Veracyte Receives New York State License for Afirma® Gene Expression Classifier

Read More

Jul 17, 2012

New Study Suggests That Use of Veracyte’s Afirma® Gene Expression Classifier Helps to Significantly Reduce Surgeries in Patients with Ambiguous Thyroid Nodule Cytology Results

Read More

Jun 25, 2012

Veracyte Announces Study Results Published Online in New England Journal of Medicine Which Suggest that Its Afirma® Gene Expression Classifier Can Reduce Unnecessary Thyroid Surgeries

Read More

Apr 16, 2012

Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis

Read More

Apr 05, 2012

Richard T. Kloos, MD, Joins Veracyte as Senior Medical Director

Read More

Jan 20, 2012

Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients

Read More

Jan 09, 2012

Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis

Read More

Sep 01, 2011

New Data Suggest Veracyte’s Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results

Read More

Sep 15, 2010

New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples

Read More

Jun 09, 2010

Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product

Read More